Metformin Management in Angiography with Stents

Introduction to Metformin-Associated Risks

The European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines state there is no adequate scientific support for routinely stopping metformin 24-48 hours before angiography in patients with normal renal function, recommending instead to carefully monitor renal function after the procedure and withhold metformin for 48 hours only if renal function deteriorates 1, 2, 3
The 2010 ESC guidelines note that checking renal function after angiography and stopping metformin when renal function deteriorates might be an acceptable alternative to universal suspension 4, 5

Calculate eGFR using standardized formula (not serum creatinine alone) to assess renal function before angiography 6, 7
The FDA mandates discontinuation of metformin in patients with eGFR 30-60 mL/min/1.73 m² undergoing iodinated contrast procedures, while the 2010 ESC guidelines recommend metformin may be stopped 48 hours before the procedure in patients with known renal failure (Class IIb, Level C) 6, 7
Renal function must be re-evaluated 48 hours after the procedure, and metformin should only be restarted if renal function is stable 6, 7

For patients with eGFR ≥60 mL/min/1.73 m² and no additional risk factors, an alternative approach (ESC-aligned) is to continue metformin, monitor renal function closely at 48 hours post-procedure, withhold for 48 hours only if deterioration occurs 1, 2, 3
Do not rely on serum creatinine alone—always calculate eGFR, as normal creatinine can mask significant renal impairment, especially in elderly or low-muscle-mass patients 6, 7
Do not restart metformin at 48 hours if the patient has ongoing hemodynamic instability, dehydration, heart failure, sepsis, or respiratory insufficiency, even if calculated eGFR appears adequate, according to guidelines other than Praxis Medical Insights 1, 2